NaviFUS (6872) reported revenue of NT$564,000 for Oct 2026, -19.0% year on year and -30.8% from the previous month. Revenue for Jan–Oct 2026 was NT$24.5 million (+167.9% year on year).
In Oct 2026, it ranked No. 149 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$564,000 | -19.0% | -30.8% |
| Sep 2026 | NT$815,000 | +22.6% | -4.3% |
| Aug 2026 | NT$852,000 | -65.3% | +7.2% |
| Jul 2026 | NT$795,000 | +32.1% | -30.4% |
| Jun 2026 | NT$1.1 million | -24.9% | +39.1% |
| May 2026 | NT$821,000 | -51.8% | -36.9% |
| Apr 2026 | NT$1.3 million | +226.3% | -92.3% |
| Mar 2026 | NT$16.9 million | +4,172.0% | +2,443.9% |
| Feb 2026 | NT$665,000 | +80.7% | +1.1% |
| Jan 2026 | NT$658,000 | +88.0% | -3.7% |
| Dec 2025 | NT$683,000 | -44.3% | +6.2% |
| Nov 2025 | NT$643,000 | +42.9% | -7.6% |
| Oct 2025 | NT$696,000 | -91.5% | +4.7% |
| Sep 2025 | NT$665,000 | -84.8% | -72.9% |
| Aug 2025 | NT$2.5 million | +2,571.7% | +308.3% |
| Jul 2025 | NT$602,000 | -92.6% | -60.4% |
| Jun 2025 | NT$1.5 million | -70.5% | -10.6% |
| May 2025 | NT$1.7 million | — | +326.6% |
| Apr 2025 | NT$399,000 | — | +0.8% |
| Mar 2025 | NT$396,000 | — | +7.6% |
| Feb 2025 | NT$368,000 | — | +5.1% |
| Jan 2025 | NT$350,000 | — | -71.5% |
| Dec 2024 | NT$1.2 million | +70.4% | +172.7% |
| Nov 2024 | NT$450,000 | — | -94.5% |
| Oct 2024 | NT$8.1 million | — | +86.6% |
Jan–Oct 2026 cumulative: NT$24.5 million (+167.9% YoY)
Other Biotech & Medical companies
Compare with peers: NaviFUS vs PEC / NaviFUS vs Lotus Pharm / NaviFUS vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
主係銷售醫療器材之收入增加所致
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16